



6 December 2023

## LTR Pharma Limited (ASX: LTP)

### Pre-Quotation Disclosure

The following information is provided to ASX Limited (**ASX**) for release to the market in connection with the official quotation of shares (**Shares**) in LTR Pharma Limited (the **Company** or **LTP**) (ASX: LTP).

Capitalised and abbreviated terms (not otherwise defined) in this document have the meaning given to them in the Replacement Prospectus lodged with the Australian Securities and Investments Commission on 9 November 2023 (**Replacement Prospectus**).

#### Completion of Offers

LTP confirms that the Offer closed on Friday, 24 November 2023 and allotment of 35,000,000 fully paid ordinary shares occurred on Tuesday, 5 December 2023 at an issue price of \$0.20 per share.

LTP also confirms the issue of 250,000 ordinary fully paid shares to a nominee of Grannus Securities Pty Ltd occurred on Tuesday, 5 December 2023 and issue of 2,792,344 options exercisable at \$0.26 each expiring three years from listing to nominees of Alpine Capital Pty Ltd occurred on Tuesday, 5 December 2023.

#### Despatch Date

The despatch date of CHESS allotment notices and issuer sponsored holding statements was Tuesday, 5 December 2023.

#### Statement of commitments

The Company confirms no change to the financial position as outlined in the Replacement Prospectus or to the expenditure program or statement of commitments as outlined in the Replacement Prospectus based on the actual amount of funds raised under the Replacement Prospectus.

#### Capital Structure

The capital structure of LTR following the completion of the Offer is as follows:

Security	Number
Fully paid ordinary shares	139,420,252
Unlisted options	4,792,344

## Restricted Securities

The following table shows the number of restricted securities on issue in LTP and the applicable restriction periods.

Security	Number	Restriction Period
Fully paid ordinary shares	69,014,714	24 months from the date of quotation
Options	4,792,344	24 months from the date of quotation



**Authorised for release by**

**Lee Rodne**

Executive Chairman

LTR Pharma Limited

**For more information, please contact:**

**LTR Pharma Limited**

Belinda Cleminson, Company Secretary

Email: [belinda.cleminson@automicgroup.com.au](mailto:belinda.cleminson@automicgroup.com.au)